Skip to Main Content

Paper Details

Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.
Neuro Oncol
25
2022
IDH mutant, Ivosidenib, LGG, LGGs, diffuse gliomas, ivosidenib, low-grade gliomas, mIDH, mIDH1 LGGs, mutant IDH, tumor
Author NameAffiliation
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory, David Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Brain Tumor Imaging Laboratory, David Geffen School of Medicine, University of California Los Angeles
Benjamin M Ellingsonuniversity of california los angeles Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Benjamin M EllingsonDavid Geffen School of Medicine, University of California Los Angeles
Grace Hyun J Kimuniversity of california los angeles Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Grace Hyun J KimDavid Geffen School of Medicine, University of California Los Angeles
Matthew S Brownuniversity of california los angeles Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Matthew S BrownDavid Geffen School of Medicine, University of California Los Angeles
Noriko SalamonDavid Geffen School of Medicine, University of California Los Angeles
Noriko SalamonDavid Geffen School of Medicine, University of California Los Angeles
Bryan YooDavid Geffen School of Medicine, University of California Los Angeles
Bryan YooDavid Geffen School of Medicine, University of California Los Angeles
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute & Harvard Medical School
Jonathan G Goldinuniversity of california los angeles Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Jonathan G GoldinDavid Geffen School of Medicine, University of California Los Angeles
Jonathan G Goldinuniversity of california los angeles Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles
Jonathan G GoldinDavid Geffen School of Medicine, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
Timothy F CloughesyDavid Geffen School of Medicine, University of California Los Angeles
  • 1 - 23

Datasets